Frontiers in Immunology (Feb 2022)

Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect

  • Ying Huang,
  • Yujing Zou,
  • Yiqun Jiao,
  • Peijie Shi,
  • Xiaoli Nie,
  • Wei Huang,
  • Chuanfeng Xiong,
  • Michael Choi,
  • Charles Huang,
  • Andrew N. Macintyre,
  • Amanda Nichols,
  • Fang Li,
  • Chuan-Yuan Li,
  • Chuan-Yuan Li,
  • Chuan-Yuan Li,
  • Nancie J. MacIver,
  • Nancie J. MacIver,
  • Nancie J. MacIver,
  • Diana M. Cardona,
  • Todd V. Brennan,
  • Zhiguo Li,
  • Nelson J. Chao,
  • Nelson J. Chao,
  • Nelson J. Chao,
  • Nelson J. Chao,
  • Jeffrey C. Rathmell,
  • Benny J. Chen,
  • Benny J. Chen

DOI
https://doi.org/10.3389/fimmu.2022.751296
Journal volume & issue
Vol. 13

Abstract

Read online

Alloreactive donor T cells undergo extensive metabolic reprogramming to become activated and induce graft-versus-host disease (GVHD) upon alloantigen encounter. It is generally thought that glycolysis, which promotes T cell growth and clonal expansion, is employed in this process. However, conflicting data have been reported regarding the requirement of glycolysis to induce T cell-mediated GVHD due to the lack of T cell-specific treatments using glycolysis inhibitors. Importantly, previous studies have not evaluated whether graft-versus-leukemia (GVL) activity is preserved in donor T cells deficient for glycolysis. As a critical component affecting the clinical outcome, it is necessary to assess the anti-tumor activity following treatment with metabolic modulators in preclinical models. In the present study, we utilized T cells selectively deficient for glucose transporter 1 (Glut1T-KO), to examine the role of glycolysis exclusively in alloreactive T cells without off-targeting effects from antigen presenting cells and other cell types that are dependent on glycolysis. We demonstrated that transfer of Glut1T-KO T cells significantly improved acute GVHD outcomes through increased apoptotic rates, impaired expansion, and decreased proinflammatory cytokine production. In addition to impaired GVHD development, donor Glut1T-KO T cells mediated sufficient GVL activity to protect recipients from tumor development. A clinically relevant approach using donor T cells treated with a small molecule inhibitor of glycolysis, 2-Deoxy-D-glucose ex vivo, further demonstrated protection from tumor development. These findings indicate that treatment with glycolysis inhibitors prior to transplantation selectively eliminates alloreactive T cells, but spares non-alloreactive T cells including those that protect against tumor growth. The present study has established a definitive role for glycolysis in acute GVHD and demonstrated that acute GVHD can be selectively prevented through targeting glycolysis.

Keywords